Samsung BioLogics Tops Swiss Drug Giant Lonza in Market Cap

SEOUL, Sept. 20 (Korea Bizwire) — South Korean biopharmaceutical maker Samsung BioLogics Co. has overhauled Swiss drug behemoth Lonza in terms of market value though its sales remain dwarfed by the latter’s top line, industry sources said Wednesday. The market capitalization of Samsung BioLogics, a unit of South Korea’s top conglomerate Samsung Group, came to [...]